Read This Before Buying Constellation Brands Stock

Constellation Brands is facing weakening fundamentals as U.S. alcohol consumption falls to an all-time low (Gallup: 54% of respondents drink), and the company reported sales that were down or stagnant in three of four quarters this year with only a 1% year‑over‑year gain in fiscal Q4 2025; comparable (non‑GAAP) net income declined in three quarters. Berkshire Hathaway has accumulated 13.4 million shares (worth about $1.77 billion at the end of Q3) after initial purchases in late 2024 and subsequent additions, but investor appetite has waned and the stock has experienced two sharp pullbacks, leaving the outlook for this pure‑play alcohol business cautiously negative for investors.

Analysis

Market structure: Declining U.S. alcohol consumption reallocates consumer spend toward non‑alcoholic beverages, experiences, and premium niche products; direct losers are pure‑play alcohol producers (STZ) facing volume declines and promotional pressure, while winners are diversified beverage majors (PEP, KO, KDP) and premium/alternative beverage entrants that can capture share and pricing. Expect inventory digestion and margin compression at STZ over next 2–6 quarters, with upward pressure on promotional intensity and temporary downward pressure on glass/aluminum orders (modest commodity demand drag of low single‑digit percent).

Risk assessment: Tail risks include an aggressive regulatory/tax regime on alcohol or litigation that could impose multi‑hundred‑million dollar costs, and operational disruption in key geographies; financial risk includes dividend/capex tradeoffs if free cash flow falls >5% YoY. Near term (days–weeks) downside driven by sentiment and vol spikes; medium term (3–12 months) driven by sequential sales trends and FY guidance; long term (years) by secular consumption decline (if U.S. drinking rate falls another 1–3% annually). Hidden dependencies: STZ’s performance hinge on international mix and premiumization execution—verify geographic % of sales within 30 days.

Trade implications: Tactical short of STZ via options to limit capital at risk while long selective defensive beverage names; use pair trades (short STZ vs long PEP/KO/KDP) for relative alpha over 3–9 months. Enter if next quarterly sales decline >2% YoY or comparable net income falls again; scale exposures if STZ stock underperforms by another 10%.

Contrarian angles: Consensus may underweight float reduction and strategic repositioning—Berkshire’s stake reduces free float and can cap downside volatility, and historical parallels (tobacco/alcohol incumbents) show cash return programs can sustain returns despite volume decline. The market may overprice secular doom: set buy triggers (e.g., STZ FCF yield ≥6% or dividend yield ≥3.5% with stable leverage) before reversing short stance.

Key Decisions for Investors

• Initiate a tactical short of STZ sized at ~1.5% of portfolio via 3‑month put spread (buy ATM put, sell 10% lower strike) within 10 trading days; increase to 3% notional if next reported quarter shows sales decline >2% YoY or comparable net income down >5% YoY.
• Establish a 1.5% long position in PEP (or KO/KDP as alternative) and short STZ 1.5% equal‑notional as a pair trade for 3–9 months; take profits if PEP/STZ relative total return outperforms by 5% or after 6 months.
• If holding STZ, implement a collar: buy 6‑month put ~7% OTM and sell a 6‑month call ~8% OTM to protect downside while collecting premium; reassess after next earnings release.
• Establish a 1% strategic long in BRK.B as a hedge/option on potential stabilization from Berkshire ownership; monitor STZ float changes and revoke/add within 12 months if Berkshire increases stake by >50% or liquidity tightens materially.